Rewriting the Story of Coronary Artery Disease
Heartflow advances coronary care by empowering clinicians with precision tools and insights to optimize care delivery and achieve the best possible outcomes. Since our inception, we’ve developed groundbreaking solutions inspired and guided by intelligence — from AI-powered 3D modeling of the heart to data-driven insights that transform how coronary artery disease (CAD) is detected, understood, and managed.
We partner closely with clinicians and healthcare teams to improve patient experiences and create personalized, efficient care pathways, all leading to the best outcomes for patients. Together, we envision a future in which coronary care is proactive and patient-centered—where CAD is detected early, managed effectively, and treated in ways that enable patients to celebrate more birthdays, create more memories, and enjoy more quality time.
Measurable Impact
Publications
Covered
At Heartflow, we are redefining what’s possible in coronary care. By combining precision, innovation, and a deep commitment to patient outcomes, we are empowering clinicians to see more, do more, and transform more lives.
”
Heartflow Timeline
Management Team
Tim has 18 years of experience leading the development and market introduction of innovative healthcare technologies.
He joined Heartflow in 2010 and held various product, technology, and commercial leadership roles to build Heartflow's product and service. Previously, Tim led design engineering at Cameron Health (acquired by Boston Scientific) to bring the world's first S-ICD from development to clinical use. He co-founded a company to develop custom-fit healthcare products and was a researcher in blood flow modeling from medical image data at Stanford. Tim holds over 140 patents and peer-reviewed publications.
He received a B.S in Engineering from Rensselaer Polytechnic Institute and M.S. in Engineering from Stanford.
Stephanie has held HR leadership positions among some of the world's leading organizations, including Edwards Lifesciences, Johnson and Johnson, Hologic, and Allergan. Most recently, she has spent time at Hugel Aesthetics, a growth-focused multinational organization where she was instrumental in growing the business more than 400% in less than two years.
Stephanie received her undergraduate degree from California State Polytechnic University, Pomona, and holds an MBA from Walden University.
Vikram spent more than 13 years in roles of increasing responsibility across strategy, business development, global marketing, regulatory affairs, and clinical affairs. Most recently, Vikram worked at Verily Life Sciences, where he was the Business Development lead for the medical device portfolio, and Medtronic, where he spent many years leading upstream marketing, business development and strategy.
Vikram has an MBA from The Wharton School of the University of Pennsylvania and a Master's degree in Biomedical Engineering from the University of Southern California. He is also a CFA Charterholder.
Angela brings over 25 years of invaluable public company and medtech, legal, and compliance experience to Heartflow. Most recently, she served as the General Counsel, Chief Compliance Officer, and Corporate Secretary of Inari Medical, Inc., a publicly-traded medical device manufacturer, where she oversaw their legal and compliance functions and was a key member of the executive leadership team. During her time at Inari, the company achieved over $500 million in revenue through high growth, commercial expansion, and innovation following the initial public offering in May 2020. Her extensive background also includes roles at CoreLogic and at the law firms of Latham & Watkins, LLP and Fried Frank.
Angela holds a JD from the University of Florida and earned a BA in French from Stetson University. She is a member of the California Bar.
Shivanth brings over 15 years of experience in the medical technology industry, spanning a multitude of roles from global commercial and marketing leadership to strategy, sales, business development and regulatory affairs. Most recently, Shivanth had been leading Heartflow's U.S. commercial enablement team to help expand availability and awareness of Heartflow's technologies to a growing number of patients with suspected coronary artery disease. Previously, he led global marketing and commercial teams at Medtronic's cardiology and vascular businesses, spearheading multiple successful multichannel marketing campaigns and product launches.
Shivanth holds an MBA from Harvard Business School and a Master's degree in Medical Devices and Diagnostic Engineering from the University of Southern California.
Cara is responsible for reimbursement strategy for Heartflow's current and future product portfolio. In addition, she works closely with Heartflow's sales team and customers on cardiovascular reimbursement and health policy related issues. With over 15 years of experience in market access strategy, Cara is well-versed in commercial payer and Medicare policies related to physician services and hospital inpatient, outpatient, and physician office-based procedures.
Prior to joining Heartflow, Cara worked at Elekta as the Sr. Director of Global Policy and at Bayer Healthcare as manager of reimbursement and health policy for their interventional radiology and cardiology divisions. Before Bayer, she advised pharmaceutical, biotechnology, and medical device companies on Medicare and private payer coding, coverage and reimbursement issues at the Neocure Group, a boutique medical technology consulting firm.
Ms. Santillo holds a master's degree from the University of Michigan's School of Public Health in Health Management and Policy and a BS in Nutritional Sciences from Cornell University with concentrations in Public Policy and Economics.
Board of Directors
Bill Weldon serves as Chairman of the Board of Directors for Heartflow. He spent more than four decades at Johnson & Johnson, where he began his career as a sales representative, moved to roles of increasing responsibility across business segments, and ultimately led the company through significant expansion and growth as Chairman and CEO. In addition to his board position at Heartflow, he currently serves on the Boards of Directors of J.P. Morgan Chase & Co., CVS Health, Chubb Corporation and Exxon Mobile Corporation; and the Board of Trustees of Quinnipiac University.
Tim Barabe brings more than 30 years of experience in the life sciences industry, across a broad range of financial and strategic roles. Most recently, Mr. Barabe served as the chief financial officer and executive vice president at Affymetrix Inc., where he led the company’s financial functions as well as the treasury, investor relations, and information technology departments. For more than 20 years, he held senior international executive roles in finance, general management, and strategic planning at Novartis AG. His roles included chief financial officer of the Sandoz Generics Business Unit, president of the CIBA Vision Corporation Specialty Lens Business Franchise, and group vice president and chief financial officer of CIBA Vision Corporation. Mr. Barabe has a Bachelor of Business Administration in finance from the University of Massachusetts (Amherst) and an MBA from the University of Chicago.
Julie Cullivan has more than 25 years of operational and technical experience across some of the world’s largest cybersecurity and IT brands. She has spent her career helping enterprise software and cloud companies scale their businesses and is a sought-after speaker on diversity and inclusion, security as a boardroom imperative, innovation and building high-impact teams. Most recently, Julie was the Chief Technology and People Officer at Forescout Technologies, and she has held executive roles focused on global sales and business operations at FireEye, Autodesk, McAfee, EMC and Oracle. She also serves on the Board of Directors for Axon Enterprise, Inc., and has a B.S. degree in Finance from Santa Clara University.
Dr. Downing joined Bain Capital in 2018. He is a Managing Director on the Bain Capital Life Sciences team. Prior to joining Bain Capital, Dr. Downing was a resident physician at the Brigham and Women’s Hospital in Boston, where he cared for patients on the inpatient medical service and in the outpatient clinic. Throughout his medical career, Dr. Downing has been an active health policy researcher and is the author of over 40 articles in the peer-reviewed scientific literature. Prior to his medical career, Dr. Downing was a consultant at McKinsey and Company where he worked with clients in the pharmaceutical, hospital and financial services industries on a wide range of strategic problems. Dr. Downing graduated from Harvard College Magna Cum Laude with a degree in Chemistry. He received an MD Cum Laude from Yale University School of Medicine.
John Farquhar is the President, Chief Executive Officer and Member of the Board of Directors of Heartflow and brings more than 20 years of experience providing strategic oversight to deliver operational excellence and outstanding performance. Most recently, John served as Vice President and General Manager of the Aortic business at Medtronic. He also served in key leadership roles for Medtronic’s Cardiovascular and Diabetes Groups, including Vice President of the Americas region for the Insulin Pump and Continuous Glucose Monitoring business unit and Vice President for Asia Pacific.
Jeffrey Lightcap serves as a Senior Managing Director of HealthCor Partners Management, L.P., a leading growth-oriented private equity fund which invests across all sectors of healthcare. HealthCor Partners is affiliated with HealthCor Management, a successful, research driven, heathcare-focused hedge fund. Prior to joining HealthCor Partners in late 2006, Mr. Lightcap was a Senior Managing Director at JLL Partners, a leading middle-market private equity fund, from 1997 to 2006. Prior to JLL Partners, Mr. Lightcap was a Managing Director at Merrill Lynch & Co., Inc., in the mergers and acquisitions group. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. and briefly at Salomon Brothers. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York in 1981 and an M.B.A. from the University of Chicago in 1985. Mr. Lightcap serves on the Board of Directors of a number of companies, Careview Communications, Inc., RTI Surgical Inc. (Nasdaq: RTIX), and KellBenx, Inc.
Wayne Riley is the President of the State University of New York (SUNY), Downstate Health Sciences University where he also holds academic rank as Professor of Internal Medicine and of Health Policy & Management. Dr. Riley is a Commissioner of the U.S. Medicare Payment Advisory Commission (MedPAC), Chair of the Board of Directors of the New York Academy of Medicine, President Emeritus of the 150,000-member American College of Physicians, which is the nation’s largest medical specialty organization, and an elected member of the prestigious National Academy of Medicine. From January 2007 until July 2013, Dr. Riley was the 10th President and Chief Executive Officer of Meharry Medical College. Prior, he served as a corporate officer and member of the senior management team as the Vice-President and Vice Dean for Health Affairs and Governmental Relations and Associate Professor of Internal Medicine at the Baylor College of Medicine in Houston, Texas.
Lonnie Smith joined Intuitive Surgical as President and CEO in June 1997, and currently serves as Chairman of the Board of Directors. During his tenure as CEO, Intuitive Surgical grew from a start-up with no revenue to over one billion dollars in revenue and approximately 1,300 employees. Prior to joining Intuitive Surgical, Mr. Smith was Senior Executive Vice President of Hillenbrand Industries. Mr. Smith joined Hillenbrand in 1978; during his tenure, he was a member of the executive committee, the office of the president and the board of directors. Mr. Smith has also held positions at The Boston Consulting Group and IBM. Mr. Smith receives his B.S.E.E. from Utah State University and an M.B.A. from Harvard Business School.
Casey Tansey joined USVP as a general partner in April 2005. A veteran of the medical device industry, Casey brings over 25 years of entrepreneurial, early-stage medical device and seasoned operating experience to USVP. During his tenure as CEO and President of Epicor Medical from 2001 to 2004, Casey, along with a dedicated team, pioneered a minimally-invasive treatment for atrial fibrillation and transformed the company into a recognized market leader. He led Epicor’s acquisition by St. Jude Medical at a valuation of more than $200 million. Prior to Epicor, Casey was CEO and President of Heartport, a public company that helped pioneer minimally-invasive cardiac surgery which is now a Johnson & Johnson company. Before that, he was with Baxter Edward’s Cardiovascular Division for nearly ten years, holding various sales and marketing positions. During his tenure at Baxter, Casey was involved in launching innovative heart valve products that have grown to be the market leaders.
Charles is a Founder, Chief Scientific Officer, and Member of the Board of Directors of Heartflow. Previously, he was an Associate professor in the Departments of Bioengineering and Surgery at Stanford University with courtesy faculty appointments in the Departments of Mechanical Engineering and Radiology. He is also currently an Adjunct Professor of Computational Engineering and Sciences at the University of Texas, Austin and a Part-time Professor of Biomedical Engineering at the Technical University of Eindhoven. He is internationally recognized for his pioneering work over the last 30 years in combining computer simulation methods with medical imaging data for patient-specific modeling of blood flow to aid in the diagnosis and treatment of cardiovascular disease. He received his B.S. degree in Mechanical Engineering, M.S. degree in Mechanical Engineering and M.S. degree in Mathematics from Rensselaer Polytechnic Institute and a Ph.D. in Mechanical Engineering from Stanford University.